Archive · 12 Sep 2026
Maharashtra FDA Reports Surge in Medicine Complaints, Enforcement
Maharashtra’s drug regulator received many more complaints than usual between June and August 2026.
People complained about medicines sold without prescriptions and Ayurvedic products making claims that were not allowed.
The regulator investigated 924 of the 1,397 complaints.
It also inspected thousands of medicine factories and shops.
Some businesses had problems such as missing qualified staff, incomplete records, or medicines that did not meet quality standards.
The regulator suspended 677 licences and cancelled 203 licences.
It seized products worth Rs 11.41 crore and registered 20 FIRs.
The increased enforcement followed Tukaram Mundhe taking charge as FDA Commissioner.
Maharashtra’s FDA received 1,397 complaints from June through August 2026, a 557% increase over the 2025-26 quarterly average.
The department investigated 924 complaints, while seizures rose 217% and seized materials were valued at Rs 11.41 crore.
Officials said the most common complaints involved prescription-free allopathic medicines and unauthorised claims by Ayurvedic products.
The FDA conducted 2,902 inspections and took action against 880 establishments, including 677 licence suspensions and 203 cancellations.
The department registered 20 FIRs after identifying manufacturing and sales violations, including substandard drugs and incomplete records.
- Who
- The Maharashtra Food and Drug Administration, under Commissioner Tukaram Mundhe, investigated complaints and took enforcement action.
- What
- The FDA reported a sharp rise in medicine-related complaints, inspections, seizures, licence actions and FIRs.
- When
- The reported activity took place from June through August 2026; the report is dated September 12, 2026.
- Where
- Maharashtra, including drug manufacturing and sales establishments across the state.
- Why
- The FDA intensified inspections and regulatory action after receiving complaints about prescription-free sales, unauthorised claims and quality-related violations.
- Complaints received
- 1,397 from June to August 2026
- Complaints investigated
- 924
- Inspections conducted
- 2,902
- Enforcement actions
- 880 cases, including 677 licence suspensions and 203 cancellations
- Seized material
- Rs 11.41 crore in value
- FIRs registered
- 20
- Most reported violations
- Allopathic medicines sold without prescriptions and Ayurvedic medicines sold with unauthorised claims